Collateral-resistance to estrogen and HER-activated growth is associated with modified AKT, ERα, and cell-cycle signaling in a breast cancer model
Kate M. Moore(Queen Mary University of London), Simon P. Langdon(MRC Institute of Genetics and Molecular Medicine)
Cited by 1
Related Papers
Expression of glycolytic enzymes in ovarian cancers and evaluation of the glycolytic pathway as a strategy for ovarian cancer treatment
|BMC Cancer|2018|107
Evaluation of carbonic anhydrase IX as a therapeutic target for inhibition of breast cancer invasion and metastasis using a series of<i>in vitro</i>breast cancer models
|Oncotarget|2015|96
HER2 regulates HIF-2α and drives an increased hypoxic response in breast cancer
|Breast Cancer Research|2019|69
Sensitivity to pertuzumab (2C4) in ovarian cancer models: cross-talk with estrogen receptor signaling
|Molecular Cancer Therapeutics|2007|55
Defining the molecular response to trastuzumab, pertuzumab and combination therapy in ovarian cancer
|British Journal of Cancer|2012|49